Clinical Trials Logo

Estrogen Receptor Positive Tumor clinical trials

View clinical trials related to Estrogen Receptor Positive Tumor.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05868226 Recruiting - Solid Tumor Clinical Trials

PRE-I-SPY Phase I/Ib Oncology Platform Program

PRE-I-SPY-PI
Start date: December 22, 2022
Phase: Phase 1
Study type: Interventional

I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.

NCT ID: NCT05333328 Recruiting - Breast Cancer Clinical Trials

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

INTERSTELLAR
Start date: February 6, 2023
Phase: Phase 4
Study type: Interventional

Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.

NCT ID: NCT04997798 Recruiting - Breast Cancer Clinical Trials

Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer

Start date: September 1, 2022
Phase: Phase 2
Study type: Interventional

This is a phase II open-label, multicenter trial assessing the efficacy of combination regimen"Dalpiciclib plus Exemestane plus trastuzumab plus pyrotinib"in early triple positive breast cancer patients.

NCT ID: NCT04601116 Recruiting - Clinical trials for Breast Cancer Female

The MASTER Study (MAmmary Cancer STatin ER Positive Study)

Start date: January 4, 2021
Phase: Phase 3
Study type: Interventional

Given the compelling evidence supporting a protective effect of statins on breast cancer recurrence, calls for prospective clinical trials have been expressed. In this trial - the MASTER trial - we hypothesize that the addition of statin treatment to the current breast cancer treatment will improve the prognosis of women with early breast cancer. This trial is designed as follows: a randomized, multicenter, double-blind, placebo-controlled comparison of standard (neo)adjuvant therapy plus placebo versus standard (neo)adjuvant therapy plus atorvastatin in patients with early breast cancer.

NCT ID: NCT04123262 Recruiting - Clinical trials for Neuroendocrine Tumors

Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression

Start date: November 13, 2019
Phase: Phase 2
Study type: Interventional

This is a single-arm, single-stage clinical study of tamoxifen for patients with well-differentiated neuroendocrine tumors and radiological progression with positive (> 1%) HR (estrogen and/or progesterone) expression by immunohistochemistry (IHC).

NCT ID: NCT03750396 Recruiting - Breast Cancer Clinical Trials

Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

CLEAR
Start date: August 1, 2018
Phase: Phase 2
Study type: Interventional

Local treatment in addition to endocrine treatment as 1st line for oligo-metastatic ER-positive/HER2-negative breast cancer.